The year 2016 finished with a whimper insofar as mergers and acquisitions (M&As) were concerned. The preceding year — 2015 — had gone down in history as a record year for M&As in the pharmaceutical and biotech space, when deals worth US $300 billion were announced.

While drug companies were not as active on the M&A front, the product sales growth in 2016 continued to stay extremely robust and the order of the top ranked drugs changed little from the previous year.

This week, PharmaCompass brings you a compilation of the top drugs of 2016 by sales revenue.

Click here to Access All the 2016 Data (Excel version available) for FREE!